PMA device
DETOUR System
Endologix, LLC · Stent Graft, Bypass, Superficial Femoral Artery (QWM, Class III) · First FDA decision Jun 7, 2023, newest Oct 9, 2025Peripheral artery disease
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
5
Breakthrough-designated
Device trials
4
Naming "DETOUR"
MAUDE reports
34
Brand "DETOUR", since 2015
PubMed studies
931
Mentioning "DETOUR"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing DETOUR System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 5 of 5 decisions filed under this name.
- DETOUR SystemPMA supplement
P220021-S006 · Decided Oct 9, 2025 · 42 days after receipt · Normal 180 Day Track No User Fee
Device type: Stent graft, bypass, superficial femoral artery (QWM) · Cardiology
- DETOUR SystemPMA supplement
P220021-S005 · Decided Sep 18, 2025 · 192 days after receipt · Normal 180 Day Track No User Fee
Device type: Stent graft, bypass, superficial femoral artery (QWM) · Cardiology
- DETOUR SystemPMA supplement
P220021-S002 · Decided Feb 14, 2025 · 169 days after receipt · Normal 180 Day Track No User Fee
Device type: Stent graft, bypass, superficial femoral artery (QWM) · Cardiology
2 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R8Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R7Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R6Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R3Updated Sep 21, 2026
- Carotid Artery Stenting in Post-Approval StudiesNational analysisReview closedCAG-00259NUpdated Sep 17, 2026
- Carotid Artery StentingNational analysisReview closedCAG-00085RUpdated Sep 17, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085NUpdated Sep 15, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "DETOUR", any status and sponsor, newest update first.
EndologixNot on our public-company list
NCT02471638 · 78 participants · Start Jan 2015 · Primary completion Sep 2018
Device: PQ Bypass System for Femoropopliteal Bypass · For: Peripheral Arterial Disease
Sites: Santiago, Chile; Leipzig, Germany; Milan, Italy · 8 sites in all
- The Percutaneous Transmural Arterial Bypass -1 Study (Post Approval Registry)Enrolling by invitation
EndologixNot on our public-company list
NCT06315023 · 450 participants (planned) · Start Oct 6, 2023 · Primary completion Jun 7, 2028
Device: DETOUR System · For: Peripheral Arterial Disease; Symptomatic Femoropopliteal Lesions
Sites: Salinas, California; Storrs, Connecticut; Washington D.C., District of Columbia · 10 sites in all
- The DETOUR 2 Clinical TrialCompleted
EndologixNot on our public-company list
NCT03119233 · 202 participants · Start Dec 13, 2017 · Primary completion Dec 22, 2021
Device: DETOUR System · For: Peripheral Arterial Disease
Sites: Scottsdale, Arizona; Jonesboro, Arkansas; Little Rock, Arkansas · 34 sites in all
1 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "DETOUR", and for the whole product code for context.
This brand
34 reports: 1 malfunction, 31 injury, 2 death
Whole product code QWM
42 reports: 1 malfunction, 38 injury, 2 death
Newest reports for this brand
- Detour System TorusInjury
3008011247-2026-00123 · Received Oct 13, 2026 · Event dated Aug 11, 2026
Device type: Stent Graft, Bypass, Superficial Femoral Artery (QWM)
Device problem as coded: Obstruction of Flow
Patient problem as coded: Ischemia; Pain; Obstruction/Occlusion
- Detour System TorusDeath
3008011247-2026-00104 · Received Sep 22, 2026
Device type: Stent Graft, Bypass, Superficial Femoral Artery (QWM)
Device problem as coded: Obstruction of Flow
Patient problem as coded: Myocardial Infarction; Obstruction/Occlusion; Vascular Dissection; Thrombosis/Thrombus; Insufficient Information
- Detour System TorusInjury
3015365904-2026-00008 · Received Aug 5, 2026
Device type: Stent Graft, Bypass, Superficial Femoral Artery (QWM)
Device problem as coded: Device Stenosis
Patient problem as coded: Bacterial Infection; Obstruction/Occlusion
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "DETOUR"[tiab]. The summary above synthesizes these.
- Taking a detour.
Dart A · Nat Rev Cancer · 2024
- My lucky detour.
Henson HC · Science · 2025
- A Dangerous Detour.
Berg DD, Kirshenbaum J, Gay E, et al. · N Engl J Med · 2019Interactive Tutorial
- Lead detour.
van den Broek LM, Westra SW, Evertz R, et al. · Neth Heart J · 2020
- A Dangerous Detour.
Berg DD, Kirshenbaum JM, Gay E, et al. · N Engl J Med · 2019Case Reports, Clinical Conference
- Lead detour.
van den Broek LM, Westra SW, Evertz R, et al. · Neth Heart J · 2020
- A detour to sterol synthesis.
Baker MAB, Brown AJ · Nat Microbiol · 2019Comment
- Detour test performance of cloned minipigs from three different clone populations.
Paganelli A, Felici M, Turini L, et al. · Vet Res Commun · 2023
- Detour of bile acid routes as therapeutic roadmap for cholemic nephropathy.
Fickert P · J Hepatol · 2024Editorial, Comment
- A circuitous detour.
Vachharajani TJ, Vachharajani V · Kidney Int · 2011Case Reports
- The detour paradigm in animal cognition.
Kabadayi C, Bobrowicz K, Osvath M · Anim Cogn · 2018Research Support, Non-U.S. Gov't, Review
- Nonlinear detour phase holography.
Wang B, Hong X, Wang K, et al. · Nanoscale · 2021
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.